GLP-1 drugs show promise for kidney transplant patients and Alzheimer's, but may increase eye problems

Key Findings

🧠 No cognitive benefits found for Alzheimer's patients without diabetes

• Meta-analysis of 112 non-diabetic patients with mild cognitive impairment or Alzheimer's found no improvement in cognitive test scores with GLP-1 drugs versus placebo

• Four randomized controlled trials showed no significant difference between treatment and placebo groups across multiple cognitive assessments

• Results contradict earlier hopes that GLP-1 drugs might protect brain function in dementia patients

👁️ Eye condition risk may be higher with GLP-1 drugs

• Analysis of 776,666 type 2 diabetes patients found GLP-1 users had a 33.9% higher risk of developing NAION (a form of sudden vision loss)

• The absolute risk increase was small—0.022% over five years—but statistically significant

• NAION causes sudden, painless vision loss and is one of the most common causes of blindness in adults

💊 SGLT2 inhibitors beat GLP-1 drugs for heart and kidney protection

• Network analysis of 117,633 patients found both drug classes equally effective at preventing heart attacks and strokes

• SGLT2 inhibitors (like Jardiance) were 25% more effective than GLP-1 drugs at preventing heart failure hospitalizations

• SGLT2 inhibitors also showed 24% better protection against kidney disease progression compared to GLP-1 drugs

🦠 Combining GLP-1 drugs with gut bacteria boosts benefits in mice

• Diabetic mice treated with semaglutide plus Akkermansia bacteria lost more weight and had better liver health than those getting semaglutide alone

• The combination reduced fatty liver disease and improved gut microbiome composition more effectively than either treatment solo

• Both treatments reduced intestinal inflammation, with additive effects when combined

🏥 Semaglutide users had lower healthcare costs despite higher drug prices

• Patients with obesity and multiple health conditions using semaglutide had 27% lower total medical costs ($891 vs $1,213 per month) compared to non-users

• Hospital costs were 59% lower ($115 vs $283 monthly), likely due to fewer hospitalizations and complications

• Annual savings reached $3,870 per patient, potentially offsetting the high cost of the medication itself

⚖️ No increased thyroid cancer risk found with GLP-1 drugs

• Five-year study of diabetes patients found no increased thyroid cancer risk with GLP-1 drugs compared to other diabetes medications

• Cancer rates were actually slightly lower: 0.30% for GLP-1 users versus 0.48% for SGLT2 inhibitor users (though not statistically significant)

• Analysis included propensity-matched groups of thousands of patients taking different diabetes drugs